Market Access & Healthcare Management Fundamentals
Focus innovative medicines
- Experts with outstanding know-how in HTA, pricing, reimbursement and launch preparation
- Learn the crucial points for successful market access
- Practical case study to apply your knowledge
Online-Seminar
From
1.690,00 €
plus VAT
Services & Process
Veranstaltung - 1.690,-€ zzgl. MwSt.
The fee includes high-quality course material for download, a certificate of participation, access to our Learning Space and technical support, including a test meeting.
Booking details
Online-Seminar
From
1.690,00 €
plus VAT
Services & Process
Veranstaltung - 1.690,-€ zzgl. MwSt.
The fee includes high-quality course material for download, a certificate of participation, access to our Learning Space and technical support, including a test meeting.
Market Access of innovative medicines in Europe - here you will learn the key concepts from strategy to roll-out.
Your speakers
Dr. Willi Schnorpfeil
WS Value & Dossier GmbH
Owner
Your speaker
Dr. Willi Schnorpfeil
WS Value & Dossier GmbH
Owner
Victoria Unmüßig
Astellas Pharma GmbH
EU HTA Lead; Global Access & Value and Public Policy
Your speaker
Victoria Unmüßig
Astellas Pharma GmbH
EU HTA Lead; Global Access & Value and Public Policy
Anne Martin
J&J Innovative Medicine
Director Contracting, Price & Analytics Hub
Your speaker
Anne Martin
J&J Innovative Medicine
Director Contracting, Price & Analytics Hub
Mona Glogger
AccessMatters GmbH
Managing Partner;
Mona Glogger is managing partner of AccessMatters GmbH, a specialized consulting company in the areas of pharmaceutical market access, reimbursement, HTA, and…
Your speaker
Mona Glogger
AccessMatters GmbH
Managing Partner;
Mona Glogger is managing partner of AccessMatters GmbH, a specialized consulting company in the areas of pharmaceutical market access, reimbursement, HTA, and pricing in Germany-all embedded within European and global commercial business strategy. Mona held held various leadership industry positions at different companies such as Bristol Myers Squibb, Celgene, AbbVie - from market access to HTA and pricing. With more than 10 years of industry experience, Mona has successfully supported product launches in cross-functional matrix teams from a business perspective and advocates for a broad understanding of market access in order to successfully and sustainably navigate complex market access environments.
What to Expect
- Structuring the European landscape: key health financing models and pharmaceutical market archetypes
- Market Access preparation: defining an integrated evidence package
- EU HTA and the interplay with national HTA systems
- (Pre) launch communication & Market Access in Germany
Who Should Attend
This training course is designed for pharmaceutical industry professionals who need a solid foundation in market access - including new market access specialists and managers as well as marketing, medical and clinical affairs teams looking to support market access activities more effectively.
Objective of the Event
Gain a solid foundation in market access at EU and national level - focused on innovative medicines.
Four industry experts will guide you through the European payer landscape: financial models, payer archetypes, and HTA implications. Germany's HTA system serves as a deep-dive example of a value-based market.
Leave with strategic and operational know-how to drive your next launch from a market access perspective.
Your Benefit
- Four industry experts with outstanding know-how in HTA, pricing, reimbursement and launch preparation guide you through the market access process
- Learn the crucial points for successful market access and avoid common pitfalls
- Practical case study to apply your knowledge
Programme
Day 1: 09:00 am - 05:00 pm
Day 2: 09:00 am - 01:30 pm
Day 1
09:00
09:20
Anne Martin
- History of healthcare systems (i.e. Bismarck, Beveridge); stakeholders, financing, developments and trends
- Structuring the European landscape: key health financing models and pharmaceutical market archetypes (cost effectiveness, comparative-effectiveness, budget-impact and hybrid systems)
- How system logics translate into pricing and reimbursement pathways
- (Country) specific examples of pricing and reimbursement, including price negotiations, value based pricing, contracting models (e.g. pay for performance), managed entry examples
- International perspective: reference pricing, launching
- Market implications: how financing models translate into pricing, reimbursement, and access decision making
[2 coffee breaks included in the morning session]
12:30
13:30
Dr Willi Schnorpfeil
- Clinical evidence (RCT) and Patient relevant evidence (PROs, RWE)
- Marketing authorisation - labelling, product information
- HEOR aspects as QALYs, only applicable in cost driven markets?
14:50
15:20
Victoria Unmüßig
- EU HTA framework and process: scope of Joint Clinical Assessments, roles of EU and national bodies, and interaction with national HTA
- Timelines and methodology: key procedural steps, assessment timelines, clinical domains, and methodological requirements
- Implications for market access strategy: evidence planning, national adaptation, and remaining areas of national decision making beyond EU HTA
- From volume to value: to what extent does EU HTA accelerate or reshape access decision making across Europe?
17:00
Welcome and introduction
09:20
Healthcare systems and the consequences for pricing & reimbursement in Europe
Healthcare systems and the consequences for pricing & reimbursement in Europe
Anne Martin
- History of healthcare systems (i.e. Bismarck, Beveridge); stakeholders, financing, developments and trends
- Structuring the European landscape: key health financing models and pharmaceutical market archetypes (cost effectiveness, comparative-effectiveness, budget-impact and hybrid systems)
- How system logics translate into pricing and reimbursement pathways
- (Country) specific examples of pricing and reimbursement, including price negotiations, value based pricing, contracting models (e.g. pay for performance), managed entry examples
- International perspective: reference pricing, launching
- Market implications: how financing models translate into pricing, reimbursement, and access decision making
[2 coffee breaks included in the morning session]
Lunch break
13:30
Market Access preparation: defining an integrated evidence package
Market Access preparation: defining an integrated evidence package
Dr Willi Schnorpfeil
- Clinical evidence (RCT) and Patient relevant evidence (PROs, RWE)
- Marketing authorisation - labelling, product information
- HEOR aspects as QALYs, only applicable in cost driven markets?
Coffee break
15:20
EU HTA and the interplay with national HTA systems
EU HTA and the interplay with national HTA systems
Victoria Unmüßig
- EU HTA framework and process: scope of Joint Clinical Assessments, roles of EU and national bodies, and interaction with national HTA
- Timelines and methodology: key procedural steps, assessment timelines, clinical domains, and methodological requirements
- Implications for market access strategy: evidence planning, national adaptation, and remaining areas of national decision making beyond EU HTA
- From volume to value: to what extent does EU HTA accelerate or reshape access decision making across Europe?
End of day one
Day 2
09:00
Mona Glogger
- Relevant stakeholders & stakeholder management
10:15
10:45
Dr Willi Schnorpfeil
- European level: European advisory boards, publications
- National level - example Germany: National KOLs
- Conflict of interests
12:00
12:15
Mona Glogger
- European access
- National access
- Regional access
13:30
09:00
Creating the Access Environment - example Germany
Creating the Access Environment - example Germany
Mona Glogger
- Relevant stakeholders & stakeholder management
Coffee break
10:45
(Pre) launch communication
(Pre) launch communication
Dr Willi Schnorpfeil
- European level: European advisory boards, publications
- National level - example Germany: National KOLs
- Conflict of interests
Short break
12:15
Case Study: Project management
Case Study: Project management
Mona Glogger
- European access
- National access
- Regional access
End of day 2
Downloads
Request the documents using our form.
Brochure
Market Access Basics
Weitere Informationen
Technical requirements
You need a reliable Internet connection to take part in our online events. To have the best possible learning experience, we recommend that you use the latest version of the Microsoft Edge or Google Chrome browsers. You will need a headset, loudspeaker or telephone to play the audio. Further information is available here. Please check beforehand that your microphone or headset and camera are working properly. Do not access our services from a VPN since there are issues with the audio over such connections.
We have integrated Zoom video conferencing software into our Learning Space for our online training courses. If you are not authorised to use Zoom, please get in touch with us so we can make alternative arrangements for you to take part in our online training.
Our Recommendations
Further Information
Your Contact Person
We are happy to advise you personally and individually.
Dr. Henriette Wolf-Klein
Department Manager
+49 6221 500-680
h.wolf-klein@forum-institut.de